Connor, Clark & Lunn Investment Management (CC&L)’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,025	Closed	-$118K	–	911
2017 Q3	$118K	Sell	10,025 -17,350	-63%	-$195K	﹤0.01%	779
2017 Q2	$287K	Sell	27,375 -600	-2%	-$6.12K	﹤0.01%	688
2017 Q1	$308K	Buy	27,975 +7,325	+35%	+$85K	﹤0.01%	723
2016 Q4	$280K	Sell	20,650 -15,450	-43%	-$216K	﹤0.01%	731
2016 Q3	$444K	Buy	36,100 +11,000	+44%	+$130K	﹤0.01%	600
2016 Q2	$275K	Buy	+25,100	New	+$281K	﹤0.01%	692

Other funds holding SCMP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SCMP Position: Q4 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 10,025 shares — an estimated $118K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SCMP in Q2 2016 and held it in 6 quarters. The position peaked at $444K in Q3 2016. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 10,025 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $118K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2016 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Sucampo Pharmaceuticals, Inc. position peaked at $444K in Q3 2016.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2017, filed 9 Feb 2018.